Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 2Cholangiocarcinoma 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Klatskin Tumor 1HIV Infections 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Endometrial Neoplasms 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Clinical Stage I Gastric Cancer AJCC v8 1Clinical Stage I Esophageal Adenocarcinoma AJCC v8 1Anus Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Rituximab 2pomalidomide 1dehydroftorafur 1Watchful Waiting 1Vincristine 1Taxes 1Radiotherapy, Intensity-Modulated 1Prednisone 1Platinum 1Paclitaxel 1Nivolumab 1Gemcitabine 1Fluorouracil 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × dehydroftorafur × 30 days × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡